Genetics Generation Advancement Corp. (4160.TWO)

TWD 64.7

(0.31%)

Long Term Debt Summary of Genetics Generation Advancement Corp.

  • Genetics Generation Advancement Corp.'s latest annual long term debt in 2023 was 10.34 Million TWD , up 496.25% from previous year.
  • Genetics Generation Advancement Corp.'s latest quarterly long term debt in 2024 Q2 was 6.38 Million TWD , down 0.0% from previous quarter.
  • Genetics Generation Advancement Corp. reported annual long term debt of 1.73 Million TWD in 2022, down -9.11% from previous year.
  • Genetics Generation Advancement Corp. reported annual long term debt of 1.9 Million TWD in 2021, down 0.0% from previous year.
  • Genetics Generation Advancement Corp. reported quarterly long term debt of 6.38 Million TWD for 2024 Q2, down 0.0% from previous quarter.
  • Genetics Generation Advancement Corp. reported quarterly long term debt of 10.34 Million TWD for 2023 FY, up 496.25% from previous quarter.

Annual Long Term Debt Chart of Genetics Generation Advancement Corp. (2023 - 2019)

Historical Annual Long Term Debt of Genetics Generation Advancement Corp. (2023 - 2019)

Year Long Term Debt Long Term Debt Growth
2023 10.34 Million TWD 496.25%
2022 1.73 Million TWD -9.11%
2021 1.9 Million TWD 0.0%
2020 - TWD 0.0%
2019 - TWD 0.0%

Peer Long Term Debt Comparison of Genetics Generation Advancement Corp.

Name Long Term Debt Long Term Debt Difference
BIONET Corp. 6.03 Million TWD -71.388%
DIVA Laboratories, Ltd. - TWD -Infinity%
Welgene Biotech Co.,Ltd. 118.97 Million TWD 91.305%
Puriblood Medical Co., Ltd. 43.7 Million TWD 76.328%
TFBS Bioscience Inc. 101.84 Million TWD 89.842%